Prostate Cell News 10.19 May 31, 2019 | |
| |
TOP STORYTerbium-161 for PSMA-Targeted Radionuclide Therapy of Prostate Cancer Terbium-161 (161Tb) was used for the radiolabeling of prostate-specific membrane antigen (PSMA)-617 at high specific activities up to 100 MBq/nmol. 161Tb-PSMA-617 was tested in vitro and in tumor-bearing mice to confirm equal properties, as previously determined for 177Lu-PSMA-617. The effects of 161Tb-PSMA-617 and 177Lu-PSMA-617 on cell viability and survival were compared in vitro using PSMA-positive PC-3 PIP tumor cells. [Eur J Nucl Med Mol Imaging] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers examined the effect of lipopolysaccharide (LPS), a major compound of Gram-negative bacteria, with stimulatory LPS on the invasion of prostate cancer (PCa) cells. LPS could enhance the invasiveness of PCa, but had no significant effect on PCa cell viability. Using protease inhibitor screening and biochemical analyses, matriptase, a member of the membrane-anchored serine protease family, was found to play a key role in LPS-induced PCa cell invasion. [Oncogene] Abstract BTF3 Sustains Cancer Stem-Like Phenotype of Prostate Cancer via Stabilization of BMI1 The authors identified that overexpression of BTF3 in PCa tissues and BTF3 expression highly correlates to stem-like traits. Cancer stem-like characteristics in PCa including self-renewal and metastatic potential were impaired by BTF3 loss and promoted by BTF3 overexpression. [J Exp Clin Cancer Res] Full Article Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death Investigators report that, instead of targeting the telomerase enzyme directly, small molecules that bind to the G-hairpin of the hTERT G-quadruplex-forming sequence killed selectively malignant cells without altering the function of normal cells. RG260 targeted the hTERT G-quadruplex stem-loop folding but not tetrad DNAs, leading to downregulation of hTERT expression. [Cell Chem Biol] Abstract | Graphical Abstract Researchers report that thieno[3,2-d]pyrimidine-based compounds, also known as the RP series, had efficacy in prostate cancer (PC) cells. The compound RP-010 was efficacious against both PC-3 and DU145 PC cells. The cytotoxicity of RP-010 was significantly lower in non-PC, CHO, and CRL-1459 cell lines. [Cancers] Full Article The most efficient transient receptor potential melastatin 8 channel (TRPM8) agonist, WS12, was encapsulated into lipid nanocapsules. The effect of the nanocarriers on channel activity and cellular physiological processes, such as cell viability and migration, were evaluated in vitro and in vivo. [Sci Rep] Full Article Targeting Prostate Cancer Cells with Enzalutamide-HDAC Inhibitor Hybrid Drug 2-75 The authors designed hybrid molecules containing partial chemical scaffolds of androgen receptor (AR) antagonist enzalutamide (Enz) and histone deacetylase inhibitors (HDACi) suberoylanilide hydroxamic acid as new anti-prostate cancer (PCa) agents. They previously demonstrated that Enz-HDACi hybrid drug 2-75 targeted both AR and Hsp90, which inhibited the growth of Enz-resistant C4-2 cells. They further investigated the molecular and cellular actions of 2-75 and tested its anti-PCa effects in vivo. [Prostate] Abstract Investigators determined whether use of a specific inhibitor of HO-1 activity, alone or in combination with metformin, affected metastatic prostate cancer cell viability under different concentrations of glucose.MTT assay and the xCELLigence system were used to evaluate cell viability and cell proliferation in DU145 human prostate cancer cells. Cell apoptosis and reactive oxygen species were analyzed by flow cytometry. [Int J Mol Sci] Full Article New analytical approaches were applied, combining miRNA and gene expression microarray, to screen differentially expressed miRNA-mRNA pairs in the normal prostate epithelial cell line RWPE-1, the highly-metastatic human prostate cancer cell line PC-3M-1E8 and the lowly metastatic cell line PC-3M-2B4. [J Cell Biochem] Abstract Synthesis of Novel Tanshinone Derivatives for Treatment of Castration-Resistant Prostate Cancer Twenty-five novel derivatives of tanshinone IIA as potential androgen receptor (AR) suppression reagents for the treatment of castration-resistant prostate cancer were synthesized. The inhibition on DHT-mediated AR transactivation and cell viability assay were performed to test the synthesized compounds. [Chem Biol Drug Des] Abstract A new series of 1,2,4-triazole containing hydrazide-hydrazones derived from (S)-naproxen was synthesized. The structures of these compounds were characterized by spectralmethods. Furthermore, molecular modeling of these compounds was studied on human methionine aminopeptidase-2. [Arch Pharm (Weinheim)] Abstract Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSProstate Cancer and Bone Metastases: The Underlying Mechanisms The authors outline the possible molecular mechanisms involved in governing bone metastases driven by prostate cancer, which further provide the basis in searching for new molecular targets for the development of potential therapy. [Int J Mol Sci] Full Article Role of Tumor-Associated Immune Cells in Prostate Cancer: Angel or Devil? Prostate cancer is the most common malignancy in the reproductive system of older males. Androgen deprivation therapy (ADT) is an important treatment for prostate cancer patients. However, almost all prostate cancer patients unavoidably progress to the castration-resistant stage after ADT treatment. [Asian J Androl] Full Article Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSTelix Pharmaceuticals Limited announced a prostate cancer imaging clinical collaboration with Winship Cancer Institute of Emory University. The trial is led by Winship radiation oncologist Ashesh Jani, MD, and Emory radiologist and nuclear medicine physician David Schuster, MD. [Telix Pharmaceutrical Limited (GlobeNewswire, Inc.)] Press Release Arvinas, Inc. announced that its lead PROTAC® protein degrader, ARV-110, has been granted Fast Track designation by the FDA for the treatment of men with metastatic castration-resistant prostate cancer whose disease has progressed after treatment with two or more systemic therapies. [Arvinas, Inc.] Press Release | |
| |
POLICY NEWSAmbitious Open-Access Plan S Delayed to Let Research Community Adapt A major push by some science agencies to make the research they fund open-access on publication — Plan S — has been delayed by a year. Funders now don’t have to start implementing the initiative until 2021, the agencies announced, to give researchers and publishers more time to adapt to the changes the bold plan requires. [Nature News] Editorial No Paper, No PhD? India Rethinks Graduate Student Policy PhD students in India will no longer be required to publish articles in academic journals before they are awarded their doctorates, if the country’s higher-education regulator adopts recommendations from a committee of researchers. [Nature News] Editorial Bipartisan Bill Would Create Forum for Discussing How to Counter US Academic Espionage Academic leaders say more dialogue is urgently needed on one issue now bedeviling the US research community: how to best protect the country against its economic and military competitors without choking off international scientific collaborations and the free flow of people and ideas. [ScienceInsider] Editorial MD Anderson Clears Researcher Flagged by NIH for Not Disclosing Foreign Ties MD Anderson Cancer Center in Houston, Texas, says it has concluded an investigation of the last of five researchers flagged by the US National Institutes of Health (NIH) for potential violations of agency rules. The investigation “confirmed non-compliance with NIH and MD Anderson rules and policies, but such violations were not in our view serious or indicative of willful malfeasance,” the center said in a statement. [ScienceInsider] Editorial
| |
EVENTSNEW 2nd Arab African International Cancer Congress (AAICC) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Researcher – Genitourinary Medical Oncology (MD Anderson Cancer Center) NEW Research Scientist – Cancer Cell Line Development (QLB Biotherapeutics, Inc.) Postdoctoral Fellow – Nanomedicine in Prostate Cancer (Queen’s University Belfast) Postdoctoral Position – Cancer Cell Biology (University of Zurich) Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK) Postdoctoral Research Position – Molecular Biology & Cancer Research (Augusta University) Postdoctoral Fellow – Prostate Cancer Biology (University of Maryland) Postdoctoral Position – Prostate Cancer (UT Health San Antonio) Postdoctoral Position – Microenvironment & Cancer (Brigham and Women’s Hospital) Postdoctoral Fellow – Prostate Cancer & Stem Cell Biology (City of Hope) Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|